Research ArticleArticle
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate
Matt D. Stevenson, Allan J. Wailoo, Jonathan C. Tosh, Monica Hernandez-Alava, Laura A. Gibson, John W. Stevens, Rachel J. Archer, Emma L. Simpson, Emma S. Hock, Adam Young and David L. Scott
The Journal of Rheumatology February 2017, jrheum.160941; DOI: https://doi.org/10.3899/jrheum.160941
Matt D. Stevenson
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Allan J. Wailoo
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Jonathan C. Tosh
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Monica Hernandez-Alava
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Laura A. Gibson
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
John W. Stevens
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Rachel J. Archer
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Emma L. Simpson
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Emma S. Hock
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Adam Young
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
David L. Scott
From the School of Health and Related Research, University of Sheffield, Sheffield; Department of Rheumatology, West Hertfordshire Hospitals National Health Service (NHS) Trust, Hertfordshire; Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK. Funding provided by the UK Health Technology Assessment (HTA) Programme of the National Institute for Health Research (NIHR), and the National Institute for Health and Care Excellence. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the NIHR Evaluation, Trials and Studies Coordinating Centre, the HTA Programme, or the Department of Health. M.D. Stevenson, PhD, Professor of Health Technology Assessment, School of Health and Related Research, University of Sheffield; A.J. Wailoo, PhD, Professor of Health Economics, School of Health and Related Research, University of Sheffield; J.C. Tosh, PhD, Research Fellow in Health Economics, School of Health and Related Research, University of Sheffield; M. Hernandez-Alava, PhD, Senior Research Fellow in Econometrics, School of Health and Related Research, University of Sheffield; L.A. Gibson, PhD, Research Associate in Econometrics, School of Health and Related Research, University of Sheffield; J.W. Stevens, PhD, Reader in Decision Science, School of Health and Related Research, University of Sheffield; R.J. Archer, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; E.L. Simpson, PhD, Research Fellow, School of Health and Related Research, University of Sheffield, E.S. Hock, PhD, Research Fellow, School of Health and Related Research, University of Sheffield; A. Young, FRCP, Professor of Clinical Rheumatology, Centre for Lifespan and Chronic Illness Research, University of Hertfordshire; D.L. Scott, MD, FRCP, Professor of Clinical Rheumatology, Department of Rheumatology, King’s College Hospital NHS Foundation Trust. Address correspondence to M.D. Stevenson, 30 Regent St., Sheffield, S1 4DA, UK. E-mail: m.d.stevenson@shef.ac.uk. Accepted for publication December 16, 2016.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate
Matt D. Stevenson, Allan J. Wailoo, Jonathan C. Tosh, Monica Hernandez-Alava, Laura A. Gibson, John W. Stevens, Rachel J. Archer, Emma L. Simpson, Emma S. Hock, Adam Young, David L. Scott
The Journal of Rheumatology Feb 2017, jrheum.160941; DOI: 10.3899/jrheum.160941
The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate
Matt D. Stevenson, Allan J. Wailoo, Jonathan C. Tosh, Monica Hernandez-Alava, Laura A. Gibson, John W. Stevens, Rachel J. Archer, Emma L. Simpson, Emma S. Hock, Adam Young, David L. Scott
The Journal of Rheumatology Feb 2017, jrheum.160941; DOI: 10.3899/jrheum.160941